Novartis' Midostaurin To Fill 30-Year Void In AML Treatment
This article was originally published in The Pink Sheet Daily
Executive Summary
Phase III data presented at ASH impress clincians, hopeful for a change in standard of care.
You may also be interested in...
AML Pipeline Update: Pharmas Pursue Big Breakthroughs In Niche Spaces
Unmet need in acute myeloid leukemia is very high, but that doesn't mean standards will be low for the many companies pursuing therapies in the space.
Finding Value Left On The Shelf: Karuna Case Study
PureTech’s gamble to take an older Eli Lilly drug off the shelf to redevelop in a new indication paid off. The company aims to replicate this 'Karuna model' in the near future.
Podcast: NodThera On The Role Of The Brain In Driving Chronic Disease
Alan Watt, CEO of NodThera, a clinical-stage biotech developing brain-penetrant NLRP3 inflammasome inhibitors to treat chronic inflammatory diseases, talks to In Vivo about the company’s pipeline and recent data publication in the field of obesity.